Latest Intellectual Property News

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Iondrive Limited has inked a binding term sheet with LAT66 Limited to apply its innovative Deep Eutectic Solvent technology to cobalt-rich concentrates from Finland’s Kuusamo projects, marking a strategic step beyond battery recycling into primary mineral processing.

Neurizon Therapeutics has been granted a key Australian patent for its lead drug candidate NUZ-001, extending protection for treatments targeting ALS, Alzheimer's, and other neurodegenerative diseases through 2041. This milestone complements earlier US patent grants and sets the stage for upcoming clinical trials.

Etherstack has secured a £14.2 million contract with the UK Home Office to provide critical software for the Emergency Services Network, reinforcing its global leadership in public safety communications.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

Wellnex Life reported an 18.2% sales decline in Q1 FY26 amid delayed IP licensing revenue and increased costs, while securing new debt facilities and exiting the medicinal cannabis segment.

Wide Open Agriculture has developed a novel lupin protein milk formulation that overcomes longstanding technological hurdles, lodging a patent to protect its innovation and gearing up for global commercialisation.

BrainChip Holdings Ltd showcased its leadership in ultra-low-power edge AI technology, emphasizing strong partnerships and a growing product portfolio targeting high-growth sectors like defense and healthcare.

BrainChip Holdings has initiated tape-out for its AKD1500 neuromorphic AI chip, targeting volume production by late Q3 2026 to meet rising demand for ultra-low-power edge AI solutions.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

FortifAI Limited reported steady revenue and significant cost reductions in Q1 FY26, while securing new contracts and advancing AI initiatives to boost operational efficiency.

PARKD Limited has successfully closed its Share Purchase Plan, raising $220,000; well above the initial $120,000 target; following a recent $780,000 placement. This capital boost underscores strong shareholder confidence in the company’s innovative building solutions.